CT-to-cath workflow OS that helps tertiary aortic centers identify, size, and transfer high-risk ascending-aorta cases for catheter repair.

1. Seed financing from institutional backers shows non-surgical ascending-aorta care is becoming a real category that hospitals must operationalize, not just a lab project.
2. Mortality up to 65 percent makes every hour of referral and treatment delay matter, creating budget-level urgency for faster intake and transfer workflows.
3. A transfemoral system combining valve, graft, and coronary perfusion ports means patient selection and procedure planning are becoming structural-heart-style workflows rather than pure open-surgery decisions.
4. Movement from preclinical validation into first-in-human use shifts the bottleneck from device invention to repeatable candidate identification, transfer coordination, and board-ready planning.
5. Structural-heart veterans joining the ecosystem suggests commercialization talent is arriving, which is usually when adjacent workflow software can wedge into the category.

Catalyst. Veritas' financing, transfemoral device design, and push toward first-in-human use show the market is moving from invention to execution, which makes patient-selection and transfer orchestration newly urgent infrastructure.

The product sits between spoke-hospital imaging, transfer centers, and tertiary aortic programs. It ingests outside CT scans and referral packets, standardizes key anatomy and acuity fields, and produces a structured case view showing whether the patient looks open-surgery-only, device-trial-eligible, or in need of immediate escalation. For the receiving center, it creates a single board-ready packet with imaging snapshots, device-sizing checkpoints, transfer status, and role-specific tasks for surgery, interventional cardiology, anesthesia, and cath-lab scheduling. For spoke hospitals, it replaces fax-and-phone escalation with a guided submission workflow that reduces back-and-forth and speeds acceptance decisions. The first release is sold as a transfer and planning layer for investigational programs, but the long-term asset is a proprietary dataset on complex-aortic anatomy, referral patterns, and conversion from diagnosis to intervention.

What's different. Most cardiovascular workflow software ends at generic imaging storage, transfer-center ticketing, or retrospective registry reporting. This company owns the narrow but high-value moment when an outside-hospital aortic diagnosis must be converted into an accepted, anatomically characterized, procedure-ready case for a specialized center. Defensibility comes from the case graph: anatomy normalization, candidate-selection heuristics, spoke-to-hub routing logic, and outcome feedback across rare but consequential interventions that incumbent transfer tools and device companies do not systematize well.

Jobs to be done

flowchart LR
  Buyer[Tertiary aortic center] --> Pain[Slow CT review and transfer coordination]
  Pain --> Product[CT-to-cath transfer control plane]
  Product --> Outcome[Faster accepted candidates and procedure-ready planning]

Executive takeaways

• The real near-term pain is not device design alone; it is converting a remote CT scan into an accepted, anatomically characterized, board-ready case quickly enough to save the patient and capture the procedure.
• The beachhead is commercially real but narrow: roughly a few hundred U.S. tertiary hubs, not a massive standalone software market, so venture upside depends on expanding from acute aortic intake into broader structural-heart and cardiovascular referral workflows.
• Adjacent vendors already cover image exchange, AI alerting, or structural-heart planning, but no incumbent owns the full outside-CT-to-transfer-to-sizing packet workflow for ascending-aorta programs.
• Category timing is the biggest risk: if transcatheter ascending-aorta programs mature slowly, the product must still prove ROI as a high-acuity transfer and planning layer for current surgical and hybrid aortic workflows.

Market definition

The relevant market is software and workflow infrastructure for tertiary aortic and structural-heart programs that must ingest outside CT data, triage high-acuity referrals, coordinate specialist acceptance, and prepare intervention-ready planning packets. The startup is not competing in generic PACS, generic transfer-center software, or generic radiology AI; it sits at the narrow operating layer where an acute aortic referral becomes a procedure-ready hub case.

Customer and buyer

Primary user is the structural-heart program director, aortic center operations lead, or senior coordinator inside a tertiary cardiovascular hub. Secondary users are transfer-center staff, imaging specialists, cardiac surgeons, and interventional cardiologists. The economic buyer is typically the cardiovascular service-line VP, chief of cardiac surgery, or structural-heart administrator who owns referral capture, downstream procedural revenue, and quality metrics.

Buying triggers

• Launching an investigational or minimally invasive ascending-aorta program turns candidate identification and transfer readiness into a board-level operating problem rather than an ad hoc surgeon workflow. [1][2][3][28][29]
• ATAAD transfer delays, incomplete handoff packets, and long-distance rerouting materially worsen outcomes, making standardized intake and routing worth paying for at regional hubs. [4][6][7][8][9][10]
• Structural-heart programs already live inside standardized CT-planning, registry, and outcomes-reporting environments, so another workflow layer is plausible when it accelerates complex-case capture. [12][13][14][15][19]

Willingness to pay

Budget logic is strongest when sold against lost referral capture, duplicated imaging, slower transfer acceptance, and downstream procedural economics. Hospitals already commit meaningful operational spend to structural-heart programs, image sharing, and planning software, so a focused aortic control plane can win if it shows faster accepted cases and fewer missed candidates rather than promising generic AI savings. [13][14][15][18][19][24]

Category dynamics

Growth signal Sustained annual TAVR growth; 2019 U.S. volume reached 72,991 procedures and exceeded SAVR, while the 2019-2022 registry still covered 786 hospitals.

Validation signals

• Veritas has already raised dedicated capital to move a transfemoral root and ascending-aorta device toward first-in-human use.
• Viz.ai already markets aortic-dissection detection and specialist alerting measured in seconds from CT completion.
• RapidAI explicitly pitches smarter transfer and treatment decisions as a service-line growth lever, validating hospital willingness to buy imaging workflow AI.
• Aorta-code pathway evidence suggests that standardized intake, transfer, and OR preparation can materially cut mortality in acute aortic syndromes.

Regulatory & technical constraints

• The workflow must preserve human clinical sign-off because acute-aortic transfer decisions sit inside high-stakes emergency and investigational contexts.
• Outside-CT ingestion depends on DICOM conformance, IHE-style systems integration, and enough metadata fidelity to support downstream planning.
• Complex aortic device programs remain subject to market-by-market approval status and protocol-specific trial workflows.
• Disease-specific handoff standards are still inconsistent, so the software must often structure data that referring sites do not provide cleanly today.

Competition comes from four adjacent stacks: AI alerting and care-coordination vendors, vendor-neutral image-exchange infrastructure, structural-heart planning suites, and the entrenched manual substitute of PACS plus phone/fax plus surgeon-by-surgeon judgment. The proposed startup wins only if it stitches those fragments into one aortic-specific operating flow.

Why incumbents do not win by default

• Image-exchange vendors. They can move CT data and reduce repeat scans, but they do not decide whether the case is minimally invasive, who should be alerted, or what sizing packet is needed next.
• AI alerting vendors. Viz.ai and RapidAI prove hospitals buy specialty workflow AI, but their center of gravity is alerting and team communication across broader disease lines, not aortic-specific transfer acceptance and board-ready planning.
• Structural-heart planning suites. Planning tools such as 3mensio, TeraRecon, Materialise, Medis, and Circle are strong once a case is already accepted and the CT is in-house, but they do not own spoke-to-hub intake or emergency routing.
• Manual transfer stack. Phone, fax, PACS review, and internal coordinators remain credible because they are familiar and flexible, but the literature shows they also create missing data, multiple handoffs, and unmeasured delay.

This company should start as a CT-to-cath transfer control plane for U.S. tertiary aortic centers and academic structural-heart programs that already receive urgent ascending-aorta referrals but still reconstruct candidacy, routing, and procedure prep through PACS review, phone calls, and ad hoc case boards. The first customer is a regional hub with 10 or more spoke hospitals and an active structural-heart program where launch of an investigational or minimally invasive ascending-aorta pathway turns transfer readiness into an executive operating problem. The wedge is deliberately narrow: ingest outside CT and referral packets, structure key anatomy and acuity fields, flag likely minimally invasive versus open-only cases, and assemble a board-ready packet for surgery, interventional, anesthesia, and transfer staff. That scope is faster to prove than a broad cardiovascular workflow platform because buyers can measure transfer-to-decision time, accepted-case capture, packet completeness, and pilot-to-production adoption inside one high-consequence workflow. The most credible near-term competitive advantage is not generic imaging AI; it is owning the handoff moment that image-exchange vendors, alerting vendors, planning suites, and manual coordinators each cover only in fragments. The market is commercially real but narrow, with research-based estimates of about $54.0M beachhead SAM and $196.5M broader U.S. structural-heart-adjacent TAM, so venture upside depends on expansion into adjacent structural-heart referral and planning workflows after the beachhead is proven. The biggest disconfirming risk is timing: if transcatheter ascending-aorta programs mature more slowly than expected, the product still must earn budget as a surgical and hybrid aortic transfer layer. Two material gaps remain unresolved in the source files: true per-hub urgent referral volume and the budget owner that most consistently signs this category.

Problem

• High-risk root and ascending-aorta patients are still transferred through phone, fax, PACS review, and surgeon-specific judgment, which delays acceptance and treatment in a pathology family with very high mortality.
• Early minimally invasive aortic programs cannot scale reliably when outside CT scans arrive incomplete, multidisciplinary review is rebuilt from scratch, and likely candidates are missed before the right hub team sees them.

Solution

• Provide an overlay workflow that ingests outside CT and referral packets, normalizes anatomy and acuity fields, and presents a structured case view with explicit clinician-in-the-loop triage between open-surgery-only, device-trial-eligible, and immediate escalation paths.
• Generate a board-ready packet with imaging snapshots, sizing checkpoints, transfer status, and role-specific tasks so surgery, structural heart, anesthesia, and transfer operations can accept and prepare the patient in one shared workflow.

Why we win

• The company targets the exact operating gap between outside-image exchange and in-house planning, where current incumbents move images, send alerts, or size accepted cases but do not own acceptance, routing, and packet assembly for urgent aortic referrals.
• If deployed at regional hubs, the product can build a hard-to-recreate dataset linking outside CT anatomy, packet completeness, transfer timing, acceptance decisions, and eventual treatment outcomes across rare but consequential cases.

Milestones

flowchart LR
  Wedge[Aortic transfer wedge] --> MVP[CT ingestion and board-ready packet MVP]
  MVP --> Proof[Faster acceptance and candidate-capture proof]
  Proof --> Expansion[Structural-heart referral platform expansion]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least a few hundred U.S. tertiary hubs experience enough urgent aortic and adjacent structural-heart workflow pain to support the estimated beachhead market.
• One regional hub can show buyer-visible ROI through faster acceptance decisions, better packet completeness, and higher candidate capture without replacing PACS or transfer-center systems.
• Clinical leaders will trust recommendation-mode candidate flagging and packet assembly in an emergency pathway as long as explicit sign-off remains with physicians.
• Early image-exchange and planning integrations can be standardized enough to keep gross margins above the target range instead of turning deployments into custom services.
• The company can expand from acute aortic intake into broader structural-heart referral workflows before the beachhead saturates.

Open diligence questions

• How many urgent ascending-aorta referrals does a top target hub actually process each year, and how many are lost before multidisciplinary review?
• Which executive budget owner most consistently signs and renews this category: structural heart, cardiac surgery, transfer operations, or enterprise imaging?
• What first-pass packet elements are most often missing from outside referrals, and how much time does each omission add to acceptance?
• How does the product win against Viz.ai, Sectra, 3mensio, and the manual transfer stack in a live pilot evaluation?
• Will device sponsors and investigational sites allow a third-party workflow layer to participate in screening and planning without protocol friction?

Model sanity

• Revenue engine. Base-case revenue is driven by converting three year-1 pilots into 12 paid hubs by Q4Y2 and then expanding to 18 hubs at roughly $300K ARR by Q4Y3.
• Must go right. The first image-ingestion and planning integrations must become repeatable enough to let gross margin clear 70% while customer count compounds.
• Model breaks if. If enterprise sales cycles slip a quarter and ARPU stays closer to $250K, the downside case nearly exhausts cash before the next fundraise.
• Next-round proof. The next financing is justified once the company shows at least two pilot-to-production conversions, repeatable integrations, and a credible path from the aortic wedge into adjacent structural-heart workflows.

Scenarios

Sensitivity

flowchart LR
  Leads[Qualified hub targets] --> Pilots[Paid pilots]
  Pilots --> Production[Annual hub contracts]
  Production --> Expansion[Adjacent workflow modules]
  Production --> Revenue[Subscription revenue]
  Expansion --> Revenue
  Revenue --> GrossProfit[Gross profit after implementation and support]
  GrossProfit --> Cash[Cash runway and next-round proof]

Flags: Year-2 ramp assumes 9 net new hubs after year 1 despite concentrated health-system procurement and buyer-power risk called out in research. · Gross margin only reaches target if image-ingestion and planning integrations standardize; custom deployment work would pressure both cash and EBITDA. · The year-3 case depends on expansion into adjacent structural-heart workflows because the standalone acute-aortic beachhead is commercially narrow.

• Program timing risk. If minimally invasive ascending-aorta programs take longer than expected to reach clinical use, the beachhead market may mature more slowly than planned. Mitigation: Sell first into current aortic-transfer and surgical-planning pain while designing the workflow to expand into adjacent structural-heart intake before full category breakout.
• Clinical liability sensitivity. An incorrect candidate flag or delayed escalation in an emergency aortic case could destroy trust with surgeons and administrators. Mitigation: Keep the product as a decision-support and orchestration layer with explicit clinician sign-off, audit trails, and conservative escalation rules from day one.
• Sparse-volume economics. Rare-case workflows can be hard to justify if the customer cannot tie faster coordination to higher case capture, trial enrollment, or downstream cardiovascular revenue. Mitigation: Start with high-volume referral hubs, prove ROI on transfer speed and saved candidate cases, and bundle the workflow into a broader cardiovascular intake platform over time.